Maze Therapeutics director Neil Kumar files Form 3

Maze Therapeutics, Inc. director Neil Kumar has filed an initial Form 3, identifying himself as a reporting person for the company’s stock.

Accepted by SEC EDGAR 03/31/2026 - 04:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director Neil Kumar has filed an initial Form 3, identifying himself as a reporting person for the company’s stock. The filing lists no reportable transactions or holdings, with all transaction counts and share amounts in the transaction summary shown as zero.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in the Maze Therapeutics (MAZE) Form 3?

The reporting person is Neil Kumar, who is identified as a director of Maze Therapeutics, Inc. The Form 3 shows him as a reporting insider but reports no transactions, holdings, or derivative positions, with all transaction and share counts recorded as zero.

What does the Maze Therapeutics (MAZE) Form 3 show about insider transactions?

The Form 3 for Maze Therapeutics, Inc. reports no insider transactions. All buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring counts are zero, and net buy-sell direction is labeled neutral, indicating no activity disclosed in this filing.

Does the Maze Therapeutics (MAZE) Form 3 report any share holdings?

The Form 3 indicates no reported holdings for the reporting person, Neil Kumar. The transaction summary shows zero shares for all categories and notes zero holding entries, with no derivative positions listed in the derivative summary section of the filing data.

What does the transaction summary indicate in the Maze Therapeutics (MAZE) Form 3?

The transaction summary shows no activity: buyCount, sellCount, acquireCount, disposeCount, exerciseCount, giftCount, and taxWithholdingCount are all zero. Net buy-sell shares are zero, and net buy-sell direction is described as neutral for this initial insider filing.

Are any derivative securities reported in the Maze Therapeutics (MAZE) Form 3?

No derivative securities are reported. The filing’s derivativeSummary is an empty list, and derivativeTransactionCount is zero. This means the Form 3 does not disclose any options, warrants, or other derivative positions associated with Neil Kumar at the time of this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/27/2026

3. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Courtney Phillips, as attorney-in-fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)